Principal stratification in causal inference

Biometrics

Volumn 58, Issue 1, 2002, Pages 21-29

  Frangakis, C E ^a   Rubin, D B ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Biomarker; Causal inference; Censoring by death; Missing data; Posttreatment variable; Principal stratification; Quality of life; Rubin causal model; Surrogate

Indexed keywords

CAUSAL INFERENCES; CAUSAL MODELING; CENSORING BY DEATH; MISSING DATA; POST TREATMENT; POSTTREATMENT VARIABLE; PRINCIPAL STRATIFICATION; QUALITY OF LIFE; RUBIN CAUSAL MODEL; SURROGATE;

BIOMARKERS;

BIOMETRY; MEDICINE;

ARTICLE; BIOSTATISTICS; DATA ANALYSIS; DISEASE COURSE; HUMAN; OUTCOMES RESEARCH; QUALITY OF LIFE; STATISTICAL MODEL;

EID: 0036188782     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.2002.00021.x     Document Type: Article

References (44)

1. Identification of causal effects using instrumental variables (with discussion)
2. The paired availability design: A proposal for evaluating epidural analgesia during labor
3. Regression analysis of grouped survival data: Informative censoring and double sampling
4. Bounds on treatment effects from studies with imperfect compliance
5. School choice in NY City: A Bayesian analysis of an imperfect randomized experiment
6. The validation of surrogate endpoints in randomized experiments
7. The validation of surrogate endpoints in meta-analyses of randomized experiments
8. Analysis of covariance: Its nature and uses
9. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project
10. Causal inference without counterfactuals (with discussion)
11. Surrogate end points in clinical trials: Are we being misled?
12. A new approach to the idiosyncratic problem of drug-noncompliance with subsequent loss to follow-up
13. Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes
14. Addressing an idiosyncrasy in estimating survival curves using doublesampling in the presence of self-selected right censoring (with discussion)
15. Clustered encouragement design with individual non-compliance: Bayesian Inference and application to Advance Directive forms (with discussion)
16. Statistical validation of intermediate endpoints for chronic diseases
17. On meta-analytic assessment of surrogate outcomes
18. Causal inference in a placebo-controlled clinical trial with binary outcome and ordered compliance
19. Inferential tools for sensitivity analysis and noncompliance in clinical trials
20. Structural equation methods in the social sciences
21. Dummy endogenous variables in a simultaneous equation system
22. Estimating the effect of an influenza vaccine in an encouragement design
23. Statistics and causal inference
24. Bayesian inference for causal effects in randomized experiments with noncompliance
25. Estimating the proportion of treatment effect explained by a surrogate marker
26. Non-parametric bounds on treatment effects
27. On the application of probability theory to agricultural experiments: Essay on principles, Section 9
28. Surrogate endpoints in clinical trials: Definition and operational criteria
29. A new approach to causal inference in mortality studies with sustained exposure periods - Application to control of the healthy worker survivor effect
30. Correction for non-compliance in equivalence trials
31. Identifiability and exchangeability of direct and indirect effects
32. Adjusting for differential rates of prophylaxis therapy for PCP in high-versus low-dose AZT treatment arms in an AIDS randomized trial
33. The consequences of adjustment for a concomitant variable that has been affected by the treatment
34. The central role of the propensity score in observational studies for causal effects
35. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome
36. Estimating causal effects of treatments in randomized and nonrandomized studies
37. Assignment to a treatment group on the basis of a covariate
38. Bayesian inference for causal effects
39. More powerful randomization-based p-values in double-blind trials with noncompliance (with discussion)
40. Comment on "causal inference without counterfactuals"
41. Adjusting for nonignorable drop-out using semiparametric nonresponse models (with discussion)
42. On estimating efficacy from clinical trials
43. Discussion of presidential address "biostatistical collaboration in medical research"